Home > Healthcare & Medical Devices > Stem Cell Therapy Market

Stem Cell Therapy Market Size, By Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Oncology, Orthopedic, Cardiovascular, Neurology), End-use (Hospitals, Clinics), COVID-19 Impact Analysis, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI3331
  • Published Date: Feb 2023
  • Report Format: PDF

Industry Statistics

Stem Cell Therapy Market size was valued at over USD 11.8 billion in 2022. Driven by the increasing occurrence of chronic ailments across the globe, the market is anticipated to grow at over 10% CAGR from 2023 to 2032.
 

Stem Cell Therapy Market

To get more details on this report: Request Free Sample PDF
 

Increasing incidence of chronic disorders such as muscular dystrophy, neurological ailments, cancer, and others in both developed and developing economies is proliferating the demand for advanced experimental medical treatment. The US reported over 608,570 deaths due to cancer and nearly 1.9 million newly diagnosed cases of the disease in 2021 alone. Such high case loads are creating a notable impetus for stem cell-based therapy, fostering stem cell therapy market progress.
 

Over time, conventional drugs and treatments have demonstrated an efficacy drop when treating chronic ailments such as cancer. Stem cell-based therapies, although still considered experimental, are regarded highly promising when it comes to treating such ailments. In fact, treatments such as mesenchymal stem cell therapy have been proven efficacious in treating inflammatory, degenerative, and autoimmune disorders due to their regenerative potential and immunoregulatory properties.
 

Ethical considerations in stem cell therapy may constrain industry development

Despite an expanding scope for product adoption, the ethical challenges linked to stem cell therapies may impede the stem cell therapy market expansion. At present, the derivation of pluripotent stem cell lines from oocytes and embryos is a highly sensitive issue of contention. There are certain risks associated with such therapies including immune rejection of the cells used in treatment. The risks during stem cell transplantation include inappropriate stem cell migration, and tumor formation, among others. Meanwhile, the demand for such therapies is also limited due to medical concerns associated with oocyte retrieval and other complications related to experimental procedures.
 

Surging orthopedic ailments among the elderly to impel therapeutic area segment progress

Stem Cell Therapy Market Share, By Therapeutic Area

To tailor this report to your specific requirements: Customize this Report

Based on therapeutic area, stem cell therapy market from orthopedic segment is expected to grow at over 9.5% CAGR from 2023 to 2032, fueled by the surging occurrence of orthopedic ailments among the elderly population. Therapeutic or treatment procedures that incorporate stem cells are believed to have the potential to facilitate faster healing of bone and cartilage defects. These regenerative therapies work for various orthopedic complications such as osteoarthritis, focal and cartilage damage among others, and effectively eliminate the need for invasive surgeries where the geriatric population have a historically low success and survival rate.
 

Healthcare infrastructure upgradation efforts to make hospitals a key revenue pocket for market

Authors: Rupali Swain, Subodh Kharad

Frequently Asked Questions (FAQ) :

Global stem cell therapy market held a valuation of over USD 11.8 billion in 2022, with Global Market Insights, Inc., projections expecting it to grow at over 10% CAGR from 2023 to 2032, driven by the surging prevalence of chronic ailments worldwide.

Hospitals end use segment was valued as over USD 6.5 billion in 2022, fueled by increasing world government focus on improving hospital infrastructure, the market is set to derive notable growth from the segment.

Europe stem cell therapy industry valuation is expected to witness over USD 8 billion by 2032, on account of the increasing occurrence of neurodegenerative diseases in the region creating a strong demand for stem cell therapies.

Some of the prominent market players include Capricor Therapeutics, Cellectis, FUJIFILM Cellular Dynamics, Inc., DiscGenics, Mesoblast Ltd., ThermoGenesis Holdings, Inc., CHIESI Farmaceutici S.p.A., and GSK plc., among others.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 15
  • Tables & Figures: 241
  • Countries covered: 26
  • Pages: 120
Inquiry Before Buying

Budget constraints? Get in touch with us for special pricing

Request Discount